Table 3.

Cases vaccinated with BNT162b2 vaccine: clinical manifestations and antibody profile

Author	Skin involvement	Myositis	ILD	Antibody profile
Theodorou et al. 2021 [6]	No	Yes	No	Unknown
Ramalingam et al. 2021 [7]	No	Yes	No	Unknown
Kaulen et al. 2021	No	Yes	No	ANA ( −) anti-PM/Scl-75 ( +)
Kaulen et al. 2021	No	Yes	No	ANA ( −) anti-SAE1 ( +)
Gouda et al. 2022	Yes	Yes	Yes	ANA ( +) 1/80 anti-RNP = 39 (< 20)
Al-Rasbi et al. 2022	No	Yes	Yes	ANA ( −)
Kim et al. 2022 [20]	Yes	Yes	No	ANA ( +) (1:160), anti-Pm/scl-75 ( +)
Vutipongsatorn et al. 2022	Yes	Yes	No	ANA ( −) anti-Mi-2a ( +) and anti-Ro-52 ( +)
Gonzalez et al. 2022	Yes	Yes	Yes	ANA ( +) 1:640 anti-MDA5 ( +)
Gonzalez et al. 2022	Yes	Yes	Yes	ΑΝΑ ( −) anti-MDA5 ( +) anti-TIF1γ ( +)
Gonzalez et al. 2022	Yes	No	Yes	ANA ( −) anti-Ro-52 ( +) anti-MDA5 ( +)
Gonzalez et al. 2022	Yes	No	Yes	ANA ( +) 1/640 anti-MDA5 ( +) anti-Ro-52 ( +)
Magen et al. 2022 [23]	No	Yes	No	ANA ( +) myositis profile ( −)
De Marco et al. 2022 [13]	No	Yes	Yes	Anti-Jo1 ( +) Ro52 ( +)
De Marco et al. 2022 [13]	No	Yes	No	ANA ( −), myositis profile ( −) anti-HMGCR +
De Marco et al. 2022 [13]	No	Yes	Yes	ANA ( −), myositis profile ( −) anti-HMGCR +
De Marco et al. 2022 [13]	No	Yes	No	ANA ( −), myositis profile ( −) anti-HMGCR +
De Marco et al. 2022 [13]	No	Yes	No	ANA + (Sm/RNP/anti-chromatin +)
Dodig et al. 2022 [24]	No	Yes	No	ANA ( +) > 1/640 anti-SRP ( +)
Wu et al. 2022 [25]	Yes	Yes	No	ANA ( −), anti-TIF-1γ ( +)
Camargo-Coronel et al. 2022 [19]	Yes	Yes	No	ANA ( −) anti-Mi2a ( +) anti-Mi2b ( +)
Kreuter et al. 2022	Yes	No	No	ANA ( +) 1/320 anti-Ro52 ( +) anti-TIF1γ ( +) anti-SRP ( +)
Holzer et al. 2022 [21]	Yes	Yes	Yes	ANA ( −) anti-MDA5 ( +) anti-Ro52
Holzer et al. 2022 [21]	Yes	No	No	ANA ( +) 1/5120 anti-MDA5 ( +)
Holzer et al. 2022 [21]	Yes	No	No	NA ( +) 1/1280 anti-MDA5 ( +) anti-NXP2 ( +)
Kitajima et al. 2022	Yes	Yes	Yes	ANA ( −) anti-MDA5 +
Kitajima et al. 2022	Yes	No	Yes	ANA ( −) anti-MDA5 +